Filing Details

Accession Number:
0001209191-21-041032
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-16 17:59:55
Reporting Period:
2021-06-15
Accepted Time:
2021-06-16 17:59:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1817713 Janux Therapeutics Inc. JANX () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1652901 Avalon Ventures Xi, L.p. 1134 Kline Street
La Jolla CA 92037
No No Yes No
1844550 Avalon Bioventures Spv I, L.p. 1134 Kline Street
La Jolla CA 92037
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-15 1,138,665 $0.00 1,330,815 No 4 C Direct
Common Stock Acquisiton 2021-06-15 2,382,191 $0.00 3,713,006 No 4 C Direct
Common Stock Acquisiton 2021-06-15 674,211 $0.00 4,387,217 No 4 C Direct
Common Stock Acquisiton 2021-06-15 2,696,843 $0.00 2,696,843 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-06-15 1,153,238 $0.00 3,850,081 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-06-15 629,411 $17.00 4,479,492 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series Seed Convertible Preferred Stock Disposition 2021-06-15 888,888 $0.00 1,138,665 $0.00
Common Stock Series Seed 2 Convertible Preferred Stock Disposition 2021-06-15 1,859,634 $0.00 2,382,191 $0.00
Common Stock Series A Convertible Preferred Stock Disposition 2021-06-15 526,316 $0.00 674,211 $0.00
Common Stock Series A Convertible Preferred Stock Disposition 2021-06-15 2,105,264 $0.00 2,696,843 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2021-06-15 900,264 $0.00 1,153,238 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
  2. The shares are directly held by Avalon Ventures XI, L.P. (Avalon Ventures). Avalon Ventures XI GP LLC (Avalon XI GP) is general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. Kevin Kinsella, Richard Levandov, Braden Bohrmann and Jay Lichter, Ph.D. are managing members of Avalon XI GP. Mr. Kinsella, Mr. Levandov, Mr. Bohrmann and Dr. Lichter share voting and investment power with respect to the shares held by Avalon Ventures. Each of such individuals disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of each such individual's actual pecuniary interest therein, if any.
  3. The shares are directly held by Avalon BioVentures SPV I, LP (ABV SPV). ABV SPV I GP LLC (ABV GP) is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter and Tighe Reardon share voting and investment power with respect to the shares held by ABV SPV. Each of such individuals disclaims beneficial ownership of all shares held by ABV SPV except to the extent of each such individual's actual pecuniary interest therein, if any.
  4. The shares were purchased in the Issuer's initial public offering.